Cardiac mapping is a general word that refers to various mapping techniques, including body surface mapping, endocardial mapping, and epicardial mapping. According to Market Stack, the Global Cardiac Mapping Market is expected to grow considerably during the forecasted period. Factors such as the prevalence of conditions like an atrial flutter, characterized by abnormally rapid heartbeats, also known as supraventricular tachycardia, are expected to drive the Cardiac Mapping Market in the forecasted period. Further, the growing population of geriatrics, the elderly, and people with chronic heart conditions is expected to drive the Cardiac Mapping Market in the forecasted period. Furthermore, an increase in technological improvements due to faster results, greater precision, and greater efficacy compared to the existing technologies in use is expected to drive the Cardiac Mapping Market in the forecasted period. However, the administration's need for more experienced and qualified professionals and the government's strict standards are expected to restrain the Cardiac Mapping Market in the forecasted period.

The prevalence of conditions like an atrial flutter, characterized by abnormally rapid heartbeats, also called supraventricular tachycardia, is rising and boosting the market for cardiac mapping. The prevalence of atrial flutter and cardiac mapping is primarily performed using radiofrequency catheters, propelling the market's expansion. Atrial fibrillation is an irregular and regularly rapid heart rhythm (arrhythmia) that can cause heart blood clots. AF surges the risk of heart failure, stroke, and other heart-related complications. Cardiac mapping helps the physician identify irregular heart rhythms. Due to this, the studied segment is predicted to hold significant market growth over the forecasted period. The atrial fibrillation segment is expected to observe substantial growth in the market due to factors such as increasing atrial fibrillation among the population and an increase in demand for cardiac mapping in atrial fibrillation therapies. Atrial fibrillation necessitates a trigger that initiates the arrhythmia and a substrate that promotes its persistence. Ablation catheters are the mainstream interface used in the majority of regions across the globe. In addition, the acceptance rate of catheter ablation systems is steadily increasing due to the growing procedural success rate in patients suffering from persistent, paroxysmal, and permanent conditions of atrial fibrillation. A sizeable proportion of patients suffering from acute atrial fibrillation, mostly like minimally invasive surgeries, and catheter ablation satisfies the condition, holding a prominent share in the market. Modern advanced mapping systems utilized in AF ablation have revealed excellent results and could pave the way to a new stage of individual ablation and substrate characterization strategies. The recent technological improvements in the mapping systems have resulted in better visualization of multiple catheters simultaneously, thus fueling product demand. Increasing the adoption rate of these devices in developed and appearing regions has resulted in an upward growth trajectory. Hence, the studied segment is predicted to grow significantly in the estimated period due to the rise in atrial fibrillation cases and the increased technological advancements in cardiac mapping.

The North American region is expected to hold a critical market share during the forecasted period due to the increasing burden of cardiac diseases, healthcare expenditures, and product launches across North America. The growing technological innovations in various developed areas will drive the industry. The prevalence of heart valve diseases is also rising due to the surged life expectancy in the elderly population. Heart valve disease is one of the most severe and common valve diseases and is likely to increase with advancing age. Thus, the growing prevalence of heart valve diseases, such as CHD, aortic stenosis, and mitral heart valve diseases, is likely to increase the demand for heart disease treatment devices, including 3D cardiac mapping systems, and drive market growth. With the increasing number of hypertension cases globally, the number of Medicare providers, such as hospitals and clinics, is growing. The rise in cardiac disease cases increases the volume of treatment procedures, including disease diagnosis and cardiac surgeries.

Moreover, various authorities have assigned multiple funds to the research and development sector to introduce new products into the industry. New entrants in the industry have raised the competition, dominating the high growth of the healthcare sector. Furthermore, an increasing number of efficient cardiologists in developed countries is expected to fuel the industry. The rising number of hospital setups in developed countries will likely fuel market growth. The increasing geriatric population across various regions is also expected to fuel the industry. Contact cardiac mapping has witnessed the fastest growth. It offers the detection of exact locations of ablation Catheters and mapping in the 3D environment. Growing incidences of cardiovascular diseases among pediatric and neonatal owing to an inactive lifestyle and a rise in obesity are vital factors for the growth. Hospitals for Cardiac Mapping are anticipated to have a significant CAGR during the forecasted period. Technological advancements in cardiac mapping and rapid increment of the distribution network of product producers for the widespread availability of contract cardiac mapping are the features that will provide traction to the market during the forecasted period. The main driver for the market growth includes the increasing prevalence of cardiac diseases worldwide; private bodies taking up initiatives also influence the market growth.

The market key players are BioSig Technologies, MicroPort Scientific Corporation, EPMap Systems, Kardium Inc., and Lepu Medical Technology.

In March 2023, Medtronic announced that the Affera Mapping and Ablation System, comprising the Sphere-9 Catheter and the Affera Prism-1 Mapping Software, has been granted the CE Mark. The complete system presents a novel electrophysiology approach by integrating the Sphere-9 Pulsed Field Ablation (PFA), Radiofrequency (RF), and High Density (HD) mapping catheter, which identifies and eliminates atrial arrhythmias (irregular and rapid heart rhythms) while offering real-time feedback through its user-friendly mapping and navigation software.

Global Cardiac Mapping Market report provides deep insight into the market's current and future state across various regions. The study comprehensively analyses the Cardiac Mapping market by segmenting based on the Type (Contact Cardiac Mapping Systems and Non-Contact Cardiac Mapping Systems), Indication (Atrial Fibrillation, Atrial Flutter, and Other Indications), and Geography (Asia-Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints and the impact of COVID-19 on the market growth in detail. The study covers and includes emerging market trends, developments, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.